European Union - English - EMA (European Medicines Agency)

schering-plough europe - interferon alfa-2b - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b: treatment of adult patients with chronic hepatitis b associated with evidence of hepatitis b viral replication (presence of hbv-dna and hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and/or fibrosis.chronic hepatitis c:adult patients:introna is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv (see section 4.4).the best way to use introna in this indication is in combination with ribavirin.chidren and adolescents:introna is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for serum hcv-rna. the decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, hcv genotype and viral load. the expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).

Singapore - English - HSA (Health Sciences Authority)

link healthcare singapore pte ltd - aldesleukin - injection, powder, for solution - 18 miu/vial - aldesleukin 18 miu/vial

Israel - English - Ministry of Health

megapharm ltd - aldesleukin - powder for solution for infusion - aldesleukin 18 miu - aldesleukin - proleukin (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic rcc). proleukin is indicated for the treatment of adults with metastatic melanoma.careful patient selection is mandatory prior to the administration of proleukin.

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - interferon gamma - solution for injection - international unit - interferons

Malta - English - Medicines Authority

boehringer ingelheim limited ellesfield avenue, bracknell, berkshire, rg12 8ys, united kingdom - interferon gamma - solution for injection - interferon gamma 2000000 iu - immunostimulants

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

clinigen healthcare ltd - interferon gamma-1b (recombinant human) - solution for injection - 200microgram/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - aldesleukin - pdr for soln inj/inf - 18 million units/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

roche products ltd - interferon alfa-2a - solution for injection - 18 miu/0.5 %v/v

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - aldesleukin 18 miu (interleukin-2 (recombinant human));   - powder for injection - 18 miu - active: aldesleukin 18 miu (interleukin-2 (recombinant human))   excipient: dibasic sodium phosphate dihydrate mannitol monobasic sodium phosphate dihydrate sodium laurilsulfate - proleukin is indicated for the treatment of metastatic renal cell carcinoma (mrcc).